The Influence of IFN-α on Blood Plasmacytoid Dendritic Cell in Chronic Myeloid Leukaemia

References

1. ↵
   1. Deininger MW,
   2. Goldman JM,
   3. Melo JV.

   The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.

   OpenUrlFREE Full Text
2. ↵
   1. Kantarjian HM,
   2. Giles FJ,
   3. O’Brien S, et al.

   Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am 1998; 12: 31-80.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Rousselot P,
   2. Huguet F,
   3. Rea D, et al.

   Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58-60.

   OpenUrlAbstract/FREE Full Text
4. ↵
   1. Liu YJ.

   IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005; 23: 275-306.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Pacanowski J,
   2. Kahi S,
   3. Baillet M, et al.

   Reduced blood CD 123+ (Lymphoid) and CD 11c+ (Myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001; 98: 3016-3021.

   OpenUrlAbstract/FREE Full Text
6. 1. Lichtner M,
   2. Rossi R,
   3. Mengoni F, et al.

   Circulating dendritic cells and interferon-a production in patients with tuberculosis: Correlation with clinical outcome and treatment response. Clin Experimen Immunol 2006; 143: 329-337.

   OpenUrl
7. ↵
   1. Båve U,
   2. Nordmark G,
   3. Lövgren T, et al.

   Activation of the type I interferon system in primary Sjögren’s syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005; 52: 1185-95.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Dzionek A,
   2. Fuchs A,
   3. Schmidt P, et al.

   BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000; 65:6037-6046.

   OpenUrl
9. ↵
   1. Krug A,
   2. Rothenfusser S,
   3. Hornung V, et al.

   Identification of CpG oligonucleotide sequences with high induction of IFN alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001, 31:2154-2163.

   OpenUrlCrossRefPubMedWeb of Science
10. 1. Peggs K,
    2. Mackinnon S.

    Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003; 348: 1048-1050.

    OpenUrlCrossRefPubMedWeb of Science
11. 1. Kantarjian HM,
    2. O’Brien S,
    3. Cortes JE, et al.

    Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033-1041.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. Bhatia R,
    2. Holtz M,
    3. Niu N, et al.

    Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701-4707.

    OpenUrlAbstract/FREE Full Text
13. ↵
    1. Kadowaki N,
    2. Antonenko S,
    3. Lau JY, et al.

    Natural interferon α/β-producing cells link innate and adaptive immunity. J Exp Med 2000; 192: 219-226.

    OpenUrlAbstract/FREE Full Text
14. ↵
    1. Alimena G,
    2. Breccia M,
    3. Luciano L, et al.

    Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate. Leuk Res 2008; 32: 255-261.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Copland M,
    2. Fraser AR,
    3. Harrison SJ, et al.

    Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia, Cancer Immunol Immunother 2005; 54: 297-306.

    OpenUrlCrossRefPubMedWeb of Science